AR057040A1 - Compuestos espiro heterociclicos y composicion farmaceutica - Google Patents

Compuestos espiro heterociclicos y composicion farmaceutica

Info

Publication number
AR057040A1
AR057040A1 ARP060102236A ARP060102236A AR057040A1 AR 057040 A1 AR057040 A1 AR 057040A1 AR P060102236 A ARP060102236 A AR P060102236A AR P060102236 A ARP060102236 A AR P060102236A AR 057040 A1 AR057040 A1 AR 057040A1
Authority
AR
Argentina
Prior art keywords
alkyl
alternately
amino
mono
bond
Prior art date
Application number
ARP060102236A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR057040A1 publication Critical patent/AR057040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta presente se refiere a compuestos heterocíclicos, composicion farmacéutica y un proceso para preparar medicamentos y particularmente utiles como inhibidores de la aldosterona sintasa. Reivindicacion 1: Compuesto de la formula general (1), donde: A es arilo o heterociclilo; U es -C(R3)(R4)-, -O-, -S(O)m-, -N(R5)- o un enlace; V es -C(R3)(R4)- o a) si U es o bien un enlace o -C(R3)(R4)-, V es alternativamente -O-, -S(O)m- o -N(R5)-, b) si U es -S(O)m-, V es alternativamente -N(R5)-, o c) si U es -N(R5)-, V es alternativamente -S(O)m-; W es -C(R3)(R4)- o a) si U es o bien un enlace o -C(R3)(R4)- y V es -C(R3)(R4)-, W es alternativamente -O-, -S(O)m- o -N(R5)-, b) si U es o bien un enlace o -C(R3)(R4)- y V es -S(O)m-, W es alternativamente -N(R5)-, c) si U es o bien un enlace o -C(R3)(R4)- y V es -N(R5)-, W es alternativamente -S(O)m-, o d) si U es -N(R5)- y V es -C(O)-, W es alternativamente -N(R5)-; X es C o, si Z es un enlace, es alternativamente N; Y es C o, si Z es C, es alternativamente N; Z es C o un enlace; el anillo que contiene a Y está insaturado al máximo; R es hidrogeno, alquil C1-8, alcoxiC1-8-alquilC0-4, halogeno, tri-alquilC1-4-sililo, deuterio o trifluormetilo; R1 es alquil C1-8, alquilC0-8- carbonilo, amino, mono- o di-alquilC1-8-amino, alquilC0-8-carbonilamino, alquilC0-8carbonil-alquilC1-8-amino, carbamoilo, mono- o di-alquilC1-8- aminocarbonilo, carboxilo, carboxi-alquilC1-4, halogeno, ciano, oxo, trifluormetilo, trifluormetoxi, alcoxi C1-8, alcoxi-C1-8carbonilo, heterociclilo o arilo, dichos radicales pueden estar sustituidos con 1-4 alquil C1-8, alquilC0-8carbonilo, halogeno, ciano, oxo, trifluormetilo, alquilC0-8-carbonilamino, alquilC0-8-carbonil-alquilC1-8-annino, carbamoilo, mono- y di-alquilC1-6-aminocarbonilo, carboxi-alquilC0-4, alcoxi C1-8, alcoxiC1-8-carbonilo, arilo o heterociclilo; R2 es: a) independientemente uno del otro, hidrogeno, alquil C1-8, alquilC0-8-carbonilo, amino, mono- y di-alquilC1-8- amino, alquilC0-8-carbonilamino, alquilC0-C8-carbonil-alquilC1-8-amino, carbamoilo, mono- o di-alquilC1-8-aminocarbonilo, carboxilo, carboxi-alquilC1-4, halogeno, ciano, oxo, trifluormetilo, trifluormetoxi, alcoxi C1-8, alcoxiC1-8-carbonilo, heterociclilo o arilo, dichos radicales pueden estar sustituidos con 1-4 alquil C1-8, alquilC0-8-carbonilo, halogeno, ciano, oxo, trifluormetilo, trifluormetoxi, alquilC0-8-carbonilamino, alquilC0-8-carbonil-alquilC1-8-amino, carbamoilo, mono- y di- alquilC1-8-aminocarbonilo, carboxi-alquilC0-4, alcoxi C1-8, alcoxiC1-8-carbonilo, arilo o heterociclilo; o b) junto con R1 es un anillo heterocíclico de 5 a 6 miembros fusionado; R3 es hidrogeno o alquil C1-8; R4 es: a) hidrogeno o alquil C1-8; o b) junto con R3 es oxo; R5 es hidrogeno, alquil C1-8 o alquilC0-8carbonilo; m es un numero 0, 1 o 2; n es un numero 0, 1 o 2; p es un numero 1, 2 o 3; y sus sales, preferiblemente sus sales farmacéuticamente utiles.
ARP060102236A 2005-05-31 2006-05-30 Compuestos espiro heterociclicos y composicion farmaceutica AR057040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH9222005 2005-05-31

Publications (1)

Publication Number Publication Date
AR057040A1 true AR057040A1 (es) 2007-11-14

Family

ID=37038333

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102236A AR057040A1 (es) 2005-05-31 2006-05-30 Compuestos espiro heterociclicos y composicion farmaceutica

Country Status (15)

Country Link
US (1) US8071774B2 (es)
EP (1) EP1896481B1 (es)
JP (1) JP5007299B2 (es)
CN (1) CN101184760A (es)
AR (1) AR057040A1 (es)
AT (1) ATE498625T1 (es)
BR (1) BRPI0611313A2 (es)
CA (1) CA2609660A1 (es)
DE (1) DE602006020139D1 (es)
ES (1) ES2358275T3 (es)
IL (1) IL187647A0 (es)
PL (1) PL1896481T3 (es)
PT (1) PT1896481E (es)
TW (1) TW200716634A (es)
WO (1) WO2006128852A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612947A (en) * 2004-05-28 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
TW200813071A (en) * 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200904416A (en) 2007-03-29 2009-02-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AU2012282109B2 (en) 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
EA201791668A1 (ru) 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
CN100404535C (zh) * 2002-08-07 2008-07-23 诺瓦提斯公司 用作治疗醛固酮介导的病症的药物的有机化合物
EP1565463B1 (en) 2002-11-18 2008-06-11 Novartis AG Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases

Also Published As

Publication number Publication date
DE602006020139D1 (de) 2011-03-31
JP5007299B2 (ja) 2012-08-22
IL187647A0 (en) 2008-08-07
PL1896481T3 (pl) 2011-07-29
WO2006128852A3 (en) 2007-02-22
ATE498625T1 (de) 2011-03-15
WO2006128852A2 (en) 2006-12-07
TW200716634A (en) 2007-05-01
JP2008542334A (ja) 2008-11-27
CN101184760A (zh) 2008-05-21
EP1896481A2 (en) 2008-03-12
PT1896481E (pt) 2011-03-23
EP1896481B1 (en) 2011-02-16
ES2358275T3 (es) 2011-05-09
US8071774B2 (en) 2011-12-06
US20100010015A1 (en) 2010-01-14
CA2609660A1 (en) 2006-12-07
BRPI0611313A2 (pt) 2011-02-22

Similar Documents

Publication Publication Date Title
AR057040A1 (es) Compuestos espiro heterociclicos y composicion farmaceutica
AR053739A1 (es) Compuestos espiro condensados como inhibidores de la aldosterona sintasa
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
AR060591A1 (es) Compuestos imidazo
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR060590A1 (es) Compuestos imidazo
AR066691A1 (es) Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
ECSP066910A (es) Polimorfo cristalino de acetato de bazedoxifeno
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR061374A1 (es) Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
AR055606A1 (es) Derivados de benzoquinazolina
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR068912A1 (es) Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure